← Back to Search

Lopinavir/ritonavir for Coronavirus (CORIPREV-LR Trial)

Phase 3
Waitlist Available
Led By Darrell Tan, MD FRCPC PhD
Research Sponsored by Darrell Tan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

CORIPREV-LR Trial Summary

This trial is testing whether lopinavir/ritonavir can prevent people from getting COVID-19. The trial will help generate key data on COVID-19 transmission and serve as a research platform for future vaccines and preventive agents.

Eligible Conditions
  • Coronavirus
  • Post-Exposure Prophylaxis

CORIPREV-LR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Microbiologic evidence of infection
Secondary outcome measures
Adverse events
Days of hospitalization attributable to COVID-19 disease
Health-related quality of life
+6 more

Side effects data

From 2008 Phase 3 trial • 337 Patients • NCT00105079
46%
Diarrhoea
33%
Nausea
17%
Vomiting
14%
Upper respiratory tract infection
8%
Headache
8%
DIZZINESS
7%
Fatigue
6%
INSOMNIA
5%
DECREASED APPETITE
3%
Bronchitis
1%
Delusion
1%
Completed suicide
1%
Bronchitis viral
1%
Clostridial infection
1%
Progressive multifocal leukoencephalopathy
1%
Septic shock
1%
Cholecystitis acute
1%
Cytolytic hepatitis
1%
Pancreatitis acute
1%
Hemiparesis
1%
Herpes zoster
1%
Hypoglycaemia
1%
Anxiety
1%
Cerebral toxoplasmosis
1%
Meningitis
1%
Meningitis aseptic
1%
Hepatic failure
1%
Kaposi's sarcoma
1%
Burkitt's lymphoma
1%
Pregnancy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lopinavir/Ritonavir
Saquinavir/Ritonavir

CORIPREV-LR Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Lopinavir/ritonavirExperimental Treatment1 Intervention
This arm will receive oral lopinavir/ritonavir 400/100 mg (or equivalent weight-based dosing) twice daily for 14 days.
Group II: ControlActive Control1 Intervention
This arm will receive no intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lopinavir/ritonavir
2005
Completed Phase 4
~5730

Find a Location

Who is running the clinical trial?

Darrell TanLead Sponsor
Unity Health TorontoLead Sponsor
539 Previous Clinical Trials
447,642 Total Patients Enrolled
Darrell Tan, MD FRCPC PhDPrincipal InvestigatorUnity Health Toronto
1 Previous Clinical Trials
52 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
Darrell Tan 2020. "COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04321174.
All > Covid
~25 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top